Pathophysiology · MU Sofia

29. Hyperthermia and malignant hyperthermia - etiology, pathogenesis, clinical manifestations.

Inside: 1 section · 15 flashcards · 2 min

Topic 29 of 168 in the MU Sofia syllabus for Pathophysiology (Medicine, Year 3). The free AceMed note covers it in 1 section, about 295 words (2 min of reading), with 15 flashcards.

In this note

  1. Hyperthermia and malignant hyperthermia – etiology, pathogenesis, and clinical manifestations.

Hyperthermia and malignant hyperthermia – etiology, pathogenesis, and clinical manifestations.

Hyperthermia

Hyperthermia is an uncontrolled increase in body temperature, without a change in hypothalamic set point.

  • Unlike fever, it results from excessive heat production or impaired heat loss.

Etiology (Causes)

  1. 1 Excessive heat production
  • Strenuous exercise (especially in hot environments).
  • Seizures or severe muscle activity (e.g., status epilepticus).
  1. 2 Impaired heat loss
  • High environmental temperatures and humidity (heat stroke).
  • Dehydration → reduced sweating.
  • Wearing heavy clothing.
  1. 3 Drug-induced
  • Anticholinergic drugs (e.g., atropine) → inhibit sweating.
  • Sympathomimetics (e.g., amphetamines) → increase metabolism.

Pathogenesis

  • Excessive heat generation and/or reduced dissipation overwhelm thermoregulatory mechanisms.
  • No adjustment of hypothalamic set point (contrast with fever).
  • Core temperature can exceed 40°C, leading to cellular protein denaturation and enzyme dysfunction.
  • Circulatory collapse may occur due to dehydration and vasodilation.

Clinical Manifestations

  • Hot, dry skin (especially in classic heat stroke).
  • Severe dehydration.
  • Confusion, delirium, loss of consciousness.
  • Tachycardia, hypotension.
  • Multiorgan dysfunction (liver, kidneys, brain).

Malignant Hyperthermia

A genetic pharmacogenetic disorder, characterized by a rapid, life-threatening hypermetabolic state triggered by certain anesthetic agents.

Etiology (Causes)

  • Triggered by volatile anesthetic gases (e.g., halothane, sevoflurane) or succinylcholine.
  • Genetic predisposition: mutation in RYR1 gene encoding the ryanodine receptor in skeletal muscle.

Pathogenesis

  • Mutated ryanodine receptor → excessive release of calcium from sarcoplasmic reticulum in skeletal muscle.
  • Uncontrolled muscle contraction → massive increase in metabolic rate.
  • Excessive ATP consumption, heat production, and lactic acidosis.
  • Hyperkalemia from muscle breakdown (rhabdomyolysis).

Clinical Manifestations

  • Rapid increase in body temperature (can exceed 41°C).
  • Generalized muscle rigidity (especially masseter muscle).
  • Tachycardia, arrhythmias (due to hyperkalemia).
  • Metabolic acidosis.
  • Myoglobinuria (brown urine due to muscle breakdown).
  • Hypercapnia (high CO₂ levels).

Treatment (Key Points)

Hyperthermia

  • Rapid cooling (cold IV fluids, ice packs).
  • Rehydration and electrolyte correction.

Malignant Hyperthermia

  • Immediate administration of dantrolene sodium (inhibits calcium release from sarcoplasmic reticulum).
  • Cooling measures.
  • Manage metabolic derangements (acidosis, hyperkalemia).

Read the full note free

The whole note is free with an AceMed account, with its 15 flashcards. Premium adds flashcard recall, highlights and Ask AI.